Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Cannot have received: VEGFR inhibitor

Prior treatment with a vascular endothelial growth factor receptor (VEGFR) -targeting tyrosine kinase inhibitor

Cannot have received: mTOR inhibitor

Prior treatment with a mammalian target of rapamycin (mTOR) inhibitor

Cannot have received: systemic chemotherapy

Exception: within 4 weeks before randomization

Systemic chemotherapy and any liver-directed or other ablative therapy within 4 weeks before randomization

Cannot have received: systemic radionuclide therapy

Exception: within 6 weeks before randomization

Systemic radionuclide therapy within 6 weeks before randomization

Cannot have received: radiation therapy

Exception: bone metastases within 2 weeks, any other radiation therapy within 4 weeks before randomization

Radiation therapy for bone metastases within 2 weeks, any other radiation therapy, except as indicated above, within 4 weeks before randomization